{
    "symbol": "OCX",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-10 21:50:03",
    "content": "  These factors may include, without limitation, risks inherent in the development and/or the commercialization of potential diagnostic tests, uncertainty and the results of clinical trials or regulatory approvals, the capacity of OncoCyte\u00e2\u0080\u0099s third-party supply blood sample analytic system to provide consistent and precise analytic results on a commercial scale, the need to obtain third-party reimbursement for patients use of any diagnostic test the company commercializes, our need and ability to obtain future capital, the maintenance of IP rights, risks inherent in strategic transactions, such as failure to realize anticipated benefits, legal, regulatory, or political changes in the applicable jurisdictions, accounting and quality controls, greater than estimated allocations of resources to develop and commercialize technologies or failure to maintain any laboratory accreditation or certification and uncertainties associated with theCOVID-19 pandemic and its possible effect on our operations. Please proceed with your question. Please proceed with your question. Please proceed with your question. Please proceed with your question. Please proceed with your question. Please proceed with your question."
}